… intravenous ganciclovir had similar efficacies for prevention of CMV disease in allogeneic
… disease in the valacyclovir group and 1 case in the ganciclovir group (table 2). No cases of …

… receive ganciclovir or placebo through a central intravenous … Our results show that prophylactic
ganciclovir is associated … -seropositive before allogeneic bone marrow transplantation. …

… in double-blind fashion, within seven days of enrollment (eg, open-label ganciclovir,
phosphonoformate, or intravenous immune globulin more than once weekly); or if they had …

… allogeneic bone marrow transplantation (BMT). In the early 1980s, interstitial pneumonitis as
a result of CMV was the most significant cause of failure after transplants … When ganciclovir …

… RJ (1 988) Cytomegalovirus pneumonia after bone marrow transplantation successfully
treated with the combination of ganciclovir and high dose intravenous immunoglobulin. Aniinls …

… ganciclovir prophylaxis given at engraftment to cytomegalovirus (CMV)-seropositive, allogeneic
bone marrow transplant … mg/kg body weight, administered intravenously twice daily for 5 …

… Cytomegalovirus (CMV) pneumonia is a major cause of death following allogeneic marrow
transplantation [ 11. Combination therapy with ganciclovir and intravenous immunoglobulin …

… that ganciclovir may be more effective in marrow transplant … ganciclovir in recipients of
allogeneic marrow transplants (dis… of ganciclovir and high-dose intravenous immune globulin. …

… By week +6, we started an antiviral treatment with ganciclovir 4.5 mg/kg/day intravenously, …
weight intravenously every second day over a period of 3 weeks. Ganciclovir administration …

… of death after allogeneic bone marrow transplantation. We … trial of ganciclovir in recipients
of bone marrow transplants who … Ganciclovir (5 mg per kilogram of body weight intravenously) …